Therapy News and Research

RSS

£20 million funding for stem cell research in the UK

Scientists at Oxford will benefit from a share of a £20 million cross-research council investment in stem cell research which was announced last month.

9 Jun 2004

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study

9 Jun 2004

New blood test may help detect breast cancer

Researchers at UT Southwestern Medical Center at Dallas have developed a blood test that can detect amplification of a certain gene found in circulating cells associated with breast cancer.

9 Jun 2004

Genetic link between hormones and migraine

Director of the Genomics Research Centre Professor Lyn Griffiths and her team of researchers at Griffith University have identified a genetic link between hormones and migraine.

9 Jun 2004

Only half of gemcitabine dose may be activated in cancer patients

The study, presented in a poster discussion session by Jason Fisher, a student at the University of Pittsburgh School of Engineering, analyzed data from 31 cancer patients given 30-minute infusions of gemcitabine to determine what percentage of the drug dose was associated with concentrations that exceeded the body's ability to activate the drug.

9 Jun 2004

Higher generic drug use in 2003 slowed the rising cost per prescription to a 7.9% increase

Generic drug use increased to a record 48% among Express Scripts' 50 million members during 2003, spurred by the use of several prominent new generics, fluoxetine, omeprazole and lisinopril.

9 Jun 2004

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).

9 Jun 2004

New medical imaging research helps diagnosis fetal brain abnormalities, epilepsy and autism

The world's leading neuroscience and radiology experts today shared new research and technological developments in medical imaging that facilitate diagnosis and breakthrough treatments of fetal brain abnormalities, epilepsy and cognitive disorders such as autism and Alzheimer's.

7 Jun 2004

Elderly leukemia patients benefit from intensive treatment

Contrary to popular belief, patients over the age of 75 with acute myelogenous leukemia (AML) do just as well as younger patients with similar chemotherapy regimens. A new study published June 7, 2004 in the online edition of CANCER

7 Jun 2004

Gene mutation found in some women may decrease effectiveness of tamoxifen breast cancer drug

Researchers from the Johns Hopkins Kimmel Cancer Center, Indiana University and the University of Michigan have found that some women have a gene mutation that may decrease the effectiveness of tamoxifen, a commonly used breast cancer drug.

7 Jun 2004

Atrasentan reduces cancer risk by 20 percent in men with advanced hormone-resistant prostate cancer

Recent clinical studies led by Johns Hopkins Kimmel Cancer Center researchers have found that a drug called atrasentan reduces the risk by 20 percent that cancer will progress in men with advanced hormone-resistant prostate cancer.

7 Jun 2004

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.

7 Jun 2004

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.

7 Jun 2004

Treatment with atorvastatin cut incidence of stroke by almost a half

Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association (ADA)2.

7 Jun 2004

Combination treatment may help type 2 diabetes patients

New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves certain markers of cardiovascular disease risk in patients with type 2 diabetes compared to metformin alone.

6 Jun 2004

Gemcitabine may help breast cancer patients with advanced disease live longer

6 Jun 2004

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers.

6 Jun 2004

Velcade major improvement over standard therapy for relapsed multiple myeloma

Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

6 Jun 2004

Neuroscientists have overcome a major obstacle in gene therapy research

Northwestern University neuroscientists have overcome a major obstacle in gene therapy research. They've devised a method that will safely deliver and regulate expression of therapeutic genes introduced into the central nervous system to treat Parkinson's disease and other neurodegenerative diseases.

5 Jun 2004

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have presented detailed 30-week data from two of the three pivotal Phase 3 studies of exenatide during a late-breaking session at the American Diabetes Association's (ADA) 64th Scientific Sessions in Orlando, Florida.

5 Jun 2004

Therapy News and Research

£20 million funding for stem cell research in the UK

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

New blood test may help detect breast cancer

Genetic link between hormones and migraine

Only half of gemcitabine dose may be activated in cancer patients

Higher generic drug use in 2003 slowed the rising cost per prescription to a 7.9% increase

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

New medical imaging research helps diagnosis fetal brain abnormalities, epilepsy and autism

Elderly leukemia patients benefit from intensive treatment

Gene mutation found in some women may decrease effectiveness of tamoxifen breast cancer drug

Atrasentan reduces cancer risk by 20 percent in men with advanced hormone-resistant prostate cancer

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Treatment with atorvastatin cut incidence of stroke by almost a half

Combination treatment may help type 2 diabetes patients

Gemcitabine may help breast cancer patients with advanced disease live longer

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

Velcade major improvement over standard therapy for relapsed multiple myeloma

Neuroscientists have overcome a major obstacle in gene therapy research

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News